Objective: To compare the validated calculators of Indonesian Prostate Cancer Risk Calculator (IPCRC) vs Korean Prostate Cancer Risk Calculator (KPCRC) vs Prostate Cancer Prevention Trial Risk Calculator (PCPT-RC) vs European Randomized Study of Screening for Prostate Cancer Risk Calculator (ERSPC-RC) in predicting prostate cancer in our patients at Hasan Sadikin Hospital Bandung. Material & methods: This study is a prospective study conducted from August 2014 – December 2015 at Urology Clinic at Hasan Sadikin Hospital that included all patients with BPH or suspected PCa who have been undergoing prostate biopsy. Variables such as age, PSA level, prostate volume (transabdominal or transrectal ultrasound) and digital rectal examination (DRE) finding were recorded. Risk calculation was generated using each risk calculator. Data were analyzed using Chi-square analysis, Kolmogorov-Smirnov, and finally receiver operating characterisitic (ROC) curve. All statistical analyses were performed with SPSS version 20. Results: There were 89 BPH and 43 PCa patients between August 2014 – December 2015. The mean age, PSA and prostate volume are 65.78 ± 8.33 years; 121.16 ± 375.76ng/ml; 55.86 ± 31.9ml respectively. Abnormal DRE was found in 27 PCas and 4 BPHs. Receiver operator curve analysis of IPCRC showed AUC 0.861 vs KPCRC (AUC=0.779) vs ERSPC-RC (AUC=0.745) vs PCPT-RC (AUC=0.794) vs PSA (AUC 0.794), sensitivity 81.4% and specificity 71.9% with cut-off point 19.67 for the IPCRC in predicting the prostate cancer in our center. Conclusion: IPCRC is better than KPCRC, PCPT-RC and ERSPC-RC in predicting prostate cancer in our center.
Prostate cancer, calculator, screening
Zhu X, Albertsten PC, Andriole GL, Roobol MJ, Schroder FH, Vickers AJ. Risk-based prostate cancer screening. Eur Urol. 2012; 61: 652–61.
Rahardjo D, Gardian STK. New cut-off point of prostate specific antigen (PSA) and PSA density (PSAD) to enhance diagnostic specificity for prostate cancer (PCA) in country with low prostate cancer incidence. Medical Journal of Indonesia. 2000; 9: 35–42.
Umbas R, Hardjowijoto S, Mochtar CA, Safriadi F, Djatisoesanto W, Sihombing AT, et al. Guideline on prostate cancer. Indonesian Urological Association; 2011.
Abouassaly R, Thompson IM, Platz EA, Klein EA. Epidemiology, etiology, and prevention of prostate cancer. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, Editors. Campbell-Walsh Urology. 10th Ed. Philadelphia: Elsevier Saunders; 2012. p. 956–1000.
Lee DH, Jung HB, Park JW, Kim KH, Kim J, Lee SW, et al. Can Western based online prostate cancer risk calculators be used to predict prostate cancer after prostate biopsy for the Korean population? Yonsei Med J. 2013; 54(3): 665–71.
Kranse R, Roobol M, Schroder FH. A graphical device to represent the outcomes of a logistic regression analysis. The Prostate. 2008; 68: 1674–80.
Payne H, Cornford P. Prostate-specific antigen: An evolving role in diagnosis, monitoring, and treatment evaluation in prostate cancer. Urol Oncol. 2011; 29: 593–601.
Stricker PD, Frydenberg M, Kneebone A, Chopra S. Informed prostate cancer risk-adjusted testing: A new paradigm. BJU Int. 2012; Supp 4: 30–4.
Yang JB, Jeong BC, Seo SI, Jeon SS, Choi HY, Lee HM. Outcome of prostate biopsy in men younger than 40 years of age with high prostate specific antigen (PSA) levels. Korean J Urol. 2010; 51: 21–4.
Hernandez DJ, Han M, Humphreys EB, Mangold LA, Taneja SS, Childs SJ, et al. Predicting the outcome of prostate biopsy: Comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2008; 103: 609–14.
Nam RK, Kattan MW, Chin JL, Trachtenberg J, Rajiv S, Ricardo R, et al. Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol. 2011; 29: 2959–64.
Schroder F, Kattan MW. The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: A systematic review. Eur Urol. 2008; 54: 274–90.
Katz DA, Jarrard DF, McHorney CA, Hillis SL, Wiebe DA, Fryback DG. Health perceptions in patients who undergo screening and workup for prostate cancer. Urology. 2007; 69: 215–20.
Ankerst DP, Boeck A, Freedland SJ, Jones JS, Cronin AM, Roobol MJ. Evaluating the prostate cancer prevention trial high grade prostate cancer risk calculator in ten international biosy cohorts: Results from the prostate biopsy collaborative group. World J Urol. 2014; 32(1): 185–91.
Poyet C, Nieboer D, Bhindi B, Kulkarni GS, Wiederkehr C, Wettstein MS, et al. Prostate cancer risk prediction using the novel versions of the European randomised study for screening of prostate cancer (ERSPC) and prostate cancer prevention trial (PCPT) risk calculators: Independent validation and comparison in a contemporary European cohort. BJU Int. 2016; 117: 401–8.
Park JY, Yoon S, Park MS, Cho DY, Park HS, Moon DG, et al. Initial biopsy outcome prediction in Korean patients-comparison of a noble web-based Korean prostate cancer risk calculator versus prostate-specific antigen testing. J Korean Med Sci. 2011; 26(1): 85–91.
Yuri P, Wangge G, Abshari F, Perdana N, Wijaya C, Tansol C, et al. Indonesian prostate cancer risk calculator (IPCRC): An application for predicting prostate cancer risk-(a multicenter study). BJU Int. 2014; 114 Supp S3: 19.